Sheldon Freeman
Sheldon Freeman
Partner at Goodmans LLP
(416) 597-6256
(416) 979-1234
333 Bay St, Suite 3400, Bay Adelaide Ctr, W Twr, Toronto, ON
Year called to bar: 1997 (ON)
Sheldon is a partner and has a leading practice in M&A, corporate finance, and securities law. He is known for his regular involvement in high-profile transactions and expertise in corporate governance. He is placed in the top tier of his peers in terms of executing complex, high-profile private and public M&A transactions, with deep experience in contested matters including shareholder activism mandates. He is particularly accomplished in structuring and implementing cross-border transactions. He has a strong corporate and securities law practice with significant expertise in completing a wide range of multifaceted transactions, acting on behalf of both issuers and underwriters in IPOs and subsequent offerings. He also has built a substantial general corporate practice, advising various clients on issues ranging from formation to shareholder disputes and liquidity events. Sheldon is recognized as a leading lawyer by The Best Lawyers in Canada in the areas of M&A, private equity, leveraged buyouts, securities, and corporate law and by The Canadian Legal Lexpert® Directory for M&A, Corporate Finance, and Securities. He is a past member of the Securities Advisory Committee (SAC) of the Ontario Securities Commission.
Sheldon Freeman is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Consistently Recommended
Canadian Legal Lexpert Directory
Consistently Recommended
Read more about Sheldon Freeman in ...
On Sept. 2, Brookfield Property Partners L.P. announced the final results of its substantial issuer bid to purchase up to 74,166,670 of its limited partnership units
Sunovion Pharmaceuticals Inc. (“Sunovion”) completed the acquisition of Cynapsus Therapeutics Inc. (“Cynapsus”) by way of plan of arrangement for approximately $841 million. The acquisition is aligned with Sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas, including neurology.
Mettrum Health Corp. (Mettrum) completed the sale of all of its issued and outstanding shares to Canopy Growth Corporation (Canopy) by plan of arrangement, whereby Mettrum shareholders received 0.7132 common shares of Canopy for each Mettrum common share held, representing consideration of $8.42 per common share and a total transaction value of approximately $430 million, based on the respective closing prices prior to announcement of the transaction.